To obtain a preventive and a therapeutic agent having inhibitory actions on graft-versus-host disease and on graft rejection in organ transplantation, comprising a specific receptor agonist as an actives ingredient.
This composition comprises a retinoic acid receptor agonist, preferably a retinoic acid receptor subtype α agonist as an active ingredient. Preferably, the agonist is a condensed ring-containing carboxylic acid derivative of the formula [L ring and R ring are condensed to form a (substituted) hetero ring; ring A and ring B are each (substituted) aromatic hydrocarbon or a (substituted) hetero ring; D is a (protected) carboxyl], to be concrete, 4-{2-[5-(5,8- dimethylnaphthalene-2-y1)pyrrolyl]benzoic acid or 4-{2-[5-(4,7- dimethylbenzofuran-2-y1)pyrrolyl]}benzoic acid.
ISHIBASHI AKIRA
TOKUHARA NAOKI
NAGAI MITSUO
JPH0971566A | 1997-03-18 | |||
JPH11500448A | 1999-01-12 | |||
JPH0276862A | 1990-03-16 | |||
JPH02240058A | 1990-09-25 | |||
JPS63255277A | 1988-10-21 | |||
JPS49126637A | 1974-12-04 |
WO1996020913A1 | 1996-07-11 | |||
WO1996020914A1 | 1996-07-11 | |||
WO1997034869A1 | 1997-09-25 |
PT MURPHY: "Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease", BONE MARROW TRANSPLANTATION, vol. 18, JPNX006061755, 1996, pages 641 - 642, XP000974473, ISSN: 0000804298